Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and ...

LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...